Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.00+0.69 (+6.10%)
Close on Nov 18, 2026Market cap $237.93MP/E –Yield –
Keros Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Keros Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$101.47M, down 32621.8% year over year. For fiscal 2025 it was $67.57M. The highest annual figure on record is $67.57M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.57M | – |
| FY2024 | Dec 31, 2024 | -$210.83M | – |
| FY2023 | Dec 31, 2023 | -$169.94M | – |
| FY2022 | Dec 31, 2022 | -$114.79M | – |
| FY2021 | Dec 31, 2021 | -$56.37M | – |
| FY2020 | Dec 31, 2020 | -$46.66M | – |
| FY2019 | Dec 31, 2019 | -$10.56M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$30.94M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.88M | -117.0% |
| Q4 FY2025 | Dec 31, 2025 | -$29.27M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.38M | – |
| Q2 FY2025 | Jun 30, 2025 | -$39.82M | – |
| Q1 FY2025 | Mar 31, 2025 | $152.04M | – |
| Q4 FY2024 | Dec 31, 2024 | -$53.25M | – |
| Q3 FY2024 | Sep 30, 2024 | -$58.66M | – |
| Q2 FY2024 | Jun 30, 2024 | -$50.44M | – |
| Q1 FY2024 | Mar 31, 2024 | -$48.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$46.46M | – |
| Q3 FY2023 | Sep 30, 2023 | -$43.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$41.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$38.87M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.96M | – |
| Q3 FY2022 | Sep 30, 2022 | -$27.98M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.13M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.87M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.77M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.29M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.95M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.91M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.50M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.73M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.33M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.65M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.86M | – |
See a number that looks wrong?